Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anton Stangelberger

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Reviews in Urology|July 29, 2008
Prostate cancer in elderly menAnton Stangelberger, Matthias Waldert, Bob Djavan
European Urology|January 19, 2008
New treatment approaches for prostate cancer based on peptide analoguesAnton Stangelberger, Andrew V Schally, Bob Djavan
BJU International|June 28, 2007
Is the era of prostate-specific antigen over?Bob Djavan, Bernardo Rocco, Anton Stangelberger, et al.
The Prostate|September 21, 2005
Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207Anton Stangelberger, Andrew V Schally, Attila Nagy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude miceAnton Stangelberger, Andrew V Schally, Jozsef L Varga, et al.
The Prostate|July 29, 2011
Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteinsAnton Stangelberger, Andrew V Schally, Ferenc G Rick, et al.
International Journal of Cancer|July 9, 2005
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancersAnton Stangelberger, Andrew V Schally, Markus Letsch, et al.
The Prostate|March 9, 2005
Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancersAnton Stangelberger, Andrew V Schally, Jozsef L Varga, et al.
The Prostate|July 13, 2007
The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancersAnton Stangelberger, Andrew V Schally, Marta Zarandi, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2005
Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signallingAnton Stangelberger, Andrew V Schally, Jozsef L Varga, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Reviews in Urology|July 29, 2008
Prostate cancer in elderly menAnton Stangelberger, Matthias Waldert, Bob Djavan
European Urology|January 19, 2008
New treatment approaches for prostate cancer based on peptide analoguesAnton Stangelberger, Andrew V Schally, Bob Djavan
BJU International|June 28, 2007
Is the era of prostate-specific antigen over?Bob Djavan, Bernardo Rocco, Anton Stangelberger, et al.
The Prostate|September 21, 2005
Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207Anton Stangelberger, Andrew V Schally, Attila Nagy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude miceAnton Stangelberger, Andrew V Schally, Jozsef L Varga, et al.
The Prostate|July 29, 2011
Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteinsAnton Stangelberger, Andrew V Schally, Ferenc G Rick, et al.
International Journal of Cancer|July 9, 2005
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancersAnton Stangelberger, Andrew V Schally, Markus Letsch, et al.
The Prostate|March 9, 2005
Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancersAnton Stangelberger, Andrew V Schally, Jozsef L Varga, et al.
The Prostate|July 13, 2007
The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancersAnton Stangelberger, Andrew V Schally, Marta Zarandi, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2005
Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signallingAnton Stangelberger, Andrew V Schally, Jozsef L Varga, et al.
Pageof 1